Sun Pharma share price: Sun Pharmaceutical's shares declined following a reported 20% YoY drop in Q1FY26 net profit, despite a 10% increase...

Motilal Oswal anticipates a recovery in NSE’s growth despite a weak Q1FY26. While revenue dipped 11% YoY, profit rose 14%. New product laun...

Macquarie remains bullish on Reliance despite a 7.5% yearly decline, assigning a Rs 1,580 target. Growth is expected across retail, Jio, an...

Portfolio review and rebalance is something we routinely talk about, but for most investors it is not an easy concept to grasp and implemen...

But retail investors do not progress much beyond asking around. They are quite constrained in their quest to become the sharp and smart equ...

This is not your typical, hyper funded consumer internet startup, as everything about it is different when compared to the other tech IPO c...

The group plans to bring out a dossier next that will include use cases that both large firms and start-ups can gain from

Apart from bringing in transparency, these developments undoubtedly did wonders by increasing trading volumes and lending more depth and re...

Market regulator Sebi will not allow shares to be bought or sold in physical format after 5 December.

The biggest determinant for market direction next week will be the RBI's rate-setting meet.

Friday’s formation of a Hammer setup on the Nifty charts after a Bearish Engulfing Pattern on Thursday is a positive sign, which shows that...

You name a problem, the sector has it. Weak capital, high bad loans, poor demand, intensifying competition, and many more.

The performance of the Indian economy in 2004-05 so far has exceeded expectations formed at the beginning of the year.

A rebound in primary market issues, particularly in initial public offerings of equities, was the most significant development in the secur...

The performance of the Indian economy in 2004-05 so far has exceeded expectations formed at the beginning of the year.